Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 11, 2023

SELL
$87.74 - $117.27 $3.12 Million - $4.18 Million
-35,608 Reduced 9.02%
359,035 $34.9 Million
Q4 2022

Feb 13, 2023

BUY
$80.93 - $108.63 $8.08 Million - $10.9 Million
99,893 Added 33.89%
394,643 $40.8 Million
Q3 2022

Nov 08, 2022

SELL
$82.16 - $96.94 $563,206 - $664,523
-6,855 Reduced 2.27%
294,750 $25 Million
Q2 2022

Aug 15, 2022

BUY
$71.48 - $86.85 $8.94 Million - $10.9 Million
125,072 Added 70.85%
301,605 $25 Million
Q1 2022

May 16, 2022

BUY
$74.28 - $92.69 $6.63 Million - $8.27 Million
89,211 Added 102.16%
176,533 $13.6 Million
Q4 2021

Feb 14, 2022

BUY
$71.72 - $91.47 $6.26 Million - $7.99 Million
87,322 New
87,322 $7.72 Million
Q1 2021

May 14, 2021

SELL
$74.73 - $90.69 $12.3 Million - $14.9 Million
-164,545 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$72.61 - $90.2 $6.83 Million - $8.49 Million
-94,108 Reduced 36.38%
164,545 $14.4 Million
Q3 2020

Nov 13, 2020

BUY
$71.87 - $131.03 $14.1 Million - $25.6 Million
195,756 Added 311.23%
258,653 $19.7 Million
Q2 2020

Aug 13, 2020

SELL
$79.55 - $124.22 $14.1 Million - $22 Million
-177,149 Reduced 73.8%
62,897 $7.76 Million
Q1 2020

May 13, 2020

SELL
$71.37 - $96.85 $14.4 Million - $19.5 Million
-201,826 Reduced 45.68%
240,046 $20.3 Million
Q4 2019

Feb 14, 2020

BUY
$64.27 - $86.37 $22.9 Million - $30.8 Million
356,976 Added 420.49%
441,872 $37.4 Million
Q2 2019

Aug 13, 2019

BUY
$80.35 - $93.9 $5.34 Million - $6.24 Million
66,402 Added 359.05%
84,896 $7.27 Million
Q1 2019

May 15, 2019

SELL
$84.2 - $98.62 $10.3 Million - $12 Million
-122,048 Reduced 86.84%
18,494 $1.64 Million
Q4 2018

Feb 14, 2019

BUY
$80.14 - $106.07 $11.3 Million - $14.9 Million
140,542 New
140,542 $12 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $13.1B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Sofinnova Investments, Inc. Portfolio

Follow Sofinnova Investments, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sofinnova Investments, Inc. with notifications on news.